Lovastatin Has Significant Activity against Zygomycetes and Interacts Synergistically with Voriconazole
Open Access
- 1 January 2006
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (1) , 96-103
- https://doi.org/10.1128/aac.50.1.96-103.2006
Abstract
Zygomycetes are emerging opportunistic molds resistant to most conventional antifungals. We evaluated the in vitro activity of lovastatin (LOV), a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, against seven clinical isolates of Zygomycetes by using standard microdilution methods in three different media, disk diffusion testing, and viability dye staining. To further study the in vivo efficacy of LOV against zygomycetes, we developed a Drosophila melanogaster model of zygomycosis. In different experiments, groups of Toll-deficient (Tl) flies fed LOV-containing food were subsequently injected with two representative Zygomycetes isolates (Mucor and Rhizopus spp.). Finally, we examined the effects of LOV on voriconazole (VRC) activity against zygomycetes in vitro by checkerboard dilution, Epsilometer test-based methods, and bis-(1,3-dibutylbarbituric acid) trimethine oxonol staining and in vivo in Tl flies fed food containing LOV plus VRC and infected with zygomycetes. LOV exhibited significant, medium, and strain-independent fungicidal activity against all Zygomycetes isolates in vitro by all testing methods (MIC50, 48.0 μg/ml; 50% minimal fungicidal concentration, 56.0 μg/ml; 50% effective concentration, 29.4 μg/ml [6.6 to 38.9 μg/ml]). Tl flies fed LOV-containing food and infected with Mucor had a significantly better 6-day survival rate than did infected Tl flies fed regular food (P = 0.0005). LOV displayed in vitro synergy with VRC against all Zygomycetes isolates (fractional inhibitory concentration index, 0.104 to 0.290) by all methods used. LOV also displayed synergy with VRC in the Drosophila model of zygomycosis (P < 0.01). LOV is significantly active against zygomycetes and synergizes with triazoles inherently resistant to them, such as VRC. The clinical significance of these findings needs to be further explored.Keywords
This publication has 33 references indexed in Scilit:
- Zygomycosis in a Tertiary‐Care Cancer Center in the Era ofAspergillus‐Active Antifungal Therapy: A Case‐Control Observational Study of 27 Recent CasesThe Journal of Infectious Diseases, 2005
- Toll‐DeficientDrosophilaFlies as a Fast, High‐Throughput Model for the Study of Antifungal Drug Efficacy against Invasive Aspergillosis andAspergillusVirulenceThe Journal of Infectious Diseases, 2005
- In Vitro Pharmacodynamics of Amphotericin B, Itraconazole, and Voriconazole againstAspergillus,Fusarium, andScedosporiumsppAntimicrobial Agents and Chemotherapy, 2005
- Pentamidine Is Active In Vitro againstFusariumSpeciesAntimicrobial Agents and Chemotherapy, 2003
- The Antifungal Echinocandin Caspofungin Acetate Kills Growing Cells of Aspergillus fumigatus In VitroAntimicrobial Agents and Chemotherapy, 2002
- Testing Conditions for Determination of Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Aspergillus spp.: NCCLS Collaborative StudyJournal of Clinical Microbiology, 2002
- Analysis of Growth Characteristics of Filamentous Fungi in Different Nutrient MediaJournal of Clinical Microbiology, 2001
- Lovastatin Triggers an Apoptosis-like Cell Death Process in the FungusMucor racemosusFungal Genetics and Biology, 1998
- The Dorsoventral Regulatory Gene Cassette spätzle/Toll/cactus Controls the Potent Antifungal Response in Drosophila AdultsCell, 1996
- Regulation of intracellular actin polymerization by prenylated cellular proteinsThe Journal of cell biology, 1992